Control of type IV collagenase activity by components or regulatory mechanism with cell-bound reactants

EMBO Journal

16, 2319-2332

DOI: 10.1093/emboj/16.9.2319

Citation Report

#	Article	IF	Citations
1	Urokinase Plasminogen Activator and Gelatinases Are Associated with Membrane Vesicles Shed by Human HT1080 Fibrosarcoma Cells. Journal of Biological Chemistry, 1997, 272, 17216-17222.	1.6	146
2	Production and Activation of Matrix Metalloprotease-9 (MMP-9) by HL-60 Promyelocytic Leukemia Cells. Biochemical and Biophysical Research Communications, 1997, 238, 842-846.	1.0	28
3	Suppression of metastatic potential and up-regulation of gelatinases and uPA in LLC by protractedin vivo treatment with dacarbazine or razoxane., 1997, 72, 1056-1061.		1
4	Urokinase induces receptor mediated brain tumor cell migration and invasion. Journal of Neuro-Oncology, 1998, 40, 215-226.	1.4	32
5	Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. Clinical and Experimental Metastasis, 1998, 16, 489-500.	1.7	94
6	Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. The Protein Journal, 1998, 17, 845-854.	1.1	28
7	Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. Inflammation, 1998, 22, 287-305.	1.7	48
8	Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate. Inflammation, 1998, 22, 599-617.	1.7	11
9	Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy, 1998, 5, 1105-1113.	2.3	125
10	Matrix Metalloproteinases in Cerebrovascular Disease. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 1163-1172.	2.4	323
11	Immunohistochemical identification of the receptor for urokinase plasminogen activator associated with fibrin deposition in normal and ectopic human placenta. Placenta, 1998, 19, 501-508.	0.7	33
12	Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development. Developmental Dynamics, 1998, 213, 27-38.	0.8	44
13	Growth plate chondrocytes store latent transforming growth factor (TGF)-β1 in their matrix through latent TGF-β1 binding protein-1., 1998, 177, 343-354.		89
14	Immunoreactivity of the ets-1 transcription factor correlates with areas of epithelial-mesenchymal transition in the developing avian heart. Anatomy and Embryology, 1998, 198, 307-315.	1.5	33
15	Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile. Journal of Cancer Research and Clinical Oncology, 1998, 124, 598-606.	1.2	38
16	Tumor and endothelial cell invasion of basement membranes. Pathology and Oncology Research, 1998, 4, 230-241.	0.9	166
17	Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney International, 1998, 54, 1976-1984.	2.6	47
18	Membrane-type metalloproteinases in tumor invasion. International Journal of Biochemistry and Cell Biology, 1998, 30, 1195-1202.	1.2	125

#	Article	IF	CITATIONS
19	Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase. Surgery, 1998, 124, 232-238.	1.0	17
20	Tumor Cell Intravasation Alu-cidated. Cell, 1998, 94, 281-284.	13.5	79
21	Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay. Cell, 1998, 94, 353-362.	13.5	419
22	Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy. Current Eye Research, 1998, 17, 836-843.	0.7	18
23	Vascular extracellular matrix remodeling in cerebral aneurysms. Journal of Neurosurgery, 1998, 89, 431-440.	0.9	171
24	Soluble Factor(s) Released from Neutrophils Activates Endothelial Cell Matrix Metalloproteinase-2. Journal of Surgical Research, 1998, 76, 79-85.	0.8	47
25	High Affinity Binding of Latent Matrix Metalloproteinase-9 to the $\hat{l}\pm 2$ (IV) Chain of Collagen IV. Journal of Biological Chemistry, 1998, 273, 10672-10681.	1.6	128
26	Review. Biological Chemistry, 1998, 379, 95-130.	1.2	31
27	Prevention of Aneurysm Development and Rupture by Local Overexpression of Plasminogen Activator Inhibitor-1. Circulation, 1998, 98, 249-255.	1.6	135
28	Identification of a Serum Gelatinase Associated With the Occurrence of Cerebral Aneurysms as Pro-Matrix Metalloproteinase-2. Stroke, 1998, 29, 1580-1583.	1.0	92
29	Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochemical Journal, 1998, 334, 345-353.	1.7	207
30	Regulation of Gelatinase Activity in Mice with Targeted Inactivation of Components of the Plasminogen/Plasmin System. Thrombosis and Haemostasis, 1998, 79, 1171-1176.	1.8	89
31	Involvement of lung interstitial proteoglycans in development of hydraulic- and elastase-induced edema. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 275, L631-L635.	1.3	33
32	Novel Regulation of Type IV Collagenase (Matrix Metalloproteinase-9 and -2) Activities by Transforming Growth Factor-Î <sup>2</sup> 1 in Human Prostate Cancer Cell Lines. Molecular Biology of the Cell, 1999, 10, 407-416.	0.9	165
33	Angiostatin Binds to Smooth Muscle Cells in the Coronary Artery and Inhibits Smooth Muscle Cell Proliferation and Migration In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2041-2048.	1.1	40
34	Insulin-Like Growth Factor I-Triggered Cell Migration and Invasion Are Mediated by Matrix Metalloproteinase-9 <sup>1</sup> . Endocrinology, 1999, 140, 1657-1664.	1.4	95
35	Nonenzymatic Interactions between Proteinases and the Cell Surface: Novel Roles in Normal and Malignant Cell Physiology. Advances in Cancer Research, 1999, 78, 103-157.	1.9	65
36	Activation of ProMMP-9 by a Plasmin/MMP-3 Cascade in a Tumor Cell Model: Regulation by Tissue Inhibitors of Metalloproteinases. Annals of the New York Academy of Sciences, 1999, 878, 372-387.	1.8	91

#	ARTICLE	IF	CITATIONS
37	Roles of MT1-MMP in the Regulation of Cell Surface Proteolysis. Annals of the New York Academy of Sciences, 1999, 878, 703-706.	1.8	5
38	Cancer invasion and tissue remodelingâ€cooperation of protease systems and cell types. Apmis, 1999, 107, 120-127.	0.9	273
39	Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 1999, 18, 4237-4246.	2.6	186
40	RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene, 1999, 18, 4718-4725.	2.6	76
41	Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. British Journal of Cancer, 1999, 80, 1137-1143.	2.9	40
42	Effects of Tissue Type Plasminogen Activator in Embolic versus Mechanical Models of Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 1316-1321.	2.4	63
43	The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 1999, 3, 15-32.	3.7	150
44	Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO Journal, 1999, 18, 4645-4656.	3.5	225
45	Matrix Metalloproteinases. Journal of Biological Chemistry, 1999, 274, 21491-21494.	1.6	3,558
46	Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Molecular Neurobiology, 1999, 19, 267-284.	1.9	206
47	The gelatin-binding site of the second type-II domain of gelatinase Ã-¿½A/MMP-2. FEBS Journal, 1999, 259, 513-518.	0.2	35
48	Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. FEBS Journal, 1999, 263, 295-304.	0.2	170
49	Functions of the fibrinolytic system in human ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology, 1999, 29, 868-878.	3.6	50
50	Biosynthesis of ?2(IV) and ?1(IV) chains of collagen IV and interactions with matrix metalloproteinase-9., 1999, 180, 131-139.		29
51	The ?v?6 integrin induces gelatinase B secretion in colon cancer cells. , 1999, 81, 90-97.		74
52	Plasmin Cleavage of the Amyloid β-Protein: Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activityâ€. Biochemistry, 1999, 38, 11570-11576.	1.2	119
53	Prothrombin promotes the invasiveness of melanoma cells by a different mechanism from thrombin. Fibrinolysis and Proteolysis, 1999, 13, 272-278.	1.1	3
54	A link between integrins and MMPs in angiogenesis. Fibrinolysis and Proteolysis, 1999, 13, 226-238.	1.1	14

#	ARTICLE	IF	Citations
55	The sensitivity of versican from rabbit lung to gelatinase A (MMP-2) and B (MMP-9) and its involvement in the development of hydraulic lung edema. FEBS Letters, 1999, 456, 93-96.	1.3	84
56	Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion. Journal of Biological Chemistry, 1999, 274, 13066-13076.	1.6	494
57	Effects of Bisphosphonate on the Release of MMP-2 from Cultured Human Osteoblasts. Tohoku Journal of Experimental Medicine, 2000, 192, 111-118.	0.5	11
58	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640.	0.2	88
59	Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochemical Journal, 2000, 345, 511-519.	1.7	66
60	Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: Association with reduced cancer cell migration., 2000, 86, 577-581.		47
61	Activation of fibroblast-derived matrix metalloproteinase-2 by colon-cancer cells in non-contact co-cultures. International Journal of Cancer, 2000, 87, 165-171.	2.3	28
62	Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor ÎBα complementary DNA into immortalized human salivary gland acinar cells: Prevention of the destruction of the acinar structure in Siögren's syndrome salivary glands. Arthritis and Rheumatism. 2000. 43. 1756-1767.	6.7	45
63	Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration. Hepatology, 2000, 31, 75-82.	3.6	149
64	Plasminogen activation in venous leg ulcers. British Journal of Dermatology, 2000, 143, 930-936.	1.4	35
65	Roles of urokinase type plasminogen activator in a brain stab wound. Brain Research, 2000, 887, 187-190.	1.1	21
66	Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO Journal, 2000, 19, 4817-4826.	3.5	83
67	The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences, 2000, 57, 25-40.	2.4	864
68	Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases — A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Research and Treatment, 2000, 61, 1-12.	1.1	66
69	A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death <i>in vivo</i> Journal, 2000, 14, 1400-1410.	0.2	109
70	Proteinase-activated Receptor-1 Regulation of Macrophage Elastase (MMP-12) Secretion by Serine Proteinases. Journal of Biological Chemistry, 2000, 275, 41243-41250.	1.6	72
71	A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB Journal, 2000, 14, 1400-1410.	0.2	95
72	Localization of Urokinase Type Plasminogen Activator to Focal Adhesions Requires Ligation of Vitronectin Integrin Receptors. Cell Adhesion and Communication, 2000, 7, 477-490.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Modulation of Urokinase-type and Tissue-type Plasminogen Activator Occurs at an Early Stage of Progessing Stages of Chronic Venous Insufficiency: Investigative Report. Acta Dermato-Venereologica, 2000, 80, 162-166.	0.6	15
74	A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties. Journal of Biological Chemistry, 2000, 275, 1993-2002.	1.6	134
75	Activated Protein C Directly Activates Human Endothelial Gelatinase A. Journal of Biological Chemistry, 2000, 275, 9095-9098.	1.6	87
76	Urokinase Redistribution from the Secreted to the Cell-Bound Fraction in Granulosa Cells of Rat Preovulatory Follicles1. Biology of Reproduction, 2000, 62, 895-903.	1.2	14
77	Degradation of Type IV Collagen by Matrix Metalloproteinases Is an Important Step in the Epithelial-Mesenchymal Transformation of the Endocardial Cushions. Developmental Biology, 2000, 227, 606-617.	0.9	83
78	Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems. Fibrinolysis and Proteolysis, 2000, 14, 175-181.	1.1	42
79	Neutrophil-derived serine proteinases enhance membrane type-1 matrix metalloproteinase–dependent tumor cell invasion. Surgery, 2000, 127, 142-147.	1.0	27
80	Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet, The, 2000, 355, 1970-1971.	6.3	37
81	Solitary Lung Tumors and Their Spontaneous Metastasis in Athymic Nude Mice Orthotopically Implanted with Human Non-Small Cell Lung Cancer. Neoplasia, 2000, 2, 315-324.	2.3	26
82	Fibrillar Amyloid β-Protein Binds Protease Nexin-2/Amyloid β-Protein Precursor: Stimulation of Its Inhibition of Coagulation Factor XIaâ€. Biochemistry, 2000, 39, 7420-7427.	1.2	22
83	Regulation of Plasmin Activity by Annexin II Tetramerâ€. Biochemistry, 2000, 39, 1021-1028.	1.2	55
84	Proteolytic Opening of the Blood-Brain Barrier During Neuroinflammation. , 2001, , 57-63.		0
85	Perivascular Cells Regulate Endothelial Membrane Type-1 Matrix Metalloproteinase Activity. Biochemical and Biophysical Research Communications, 2001, 282, 463-473.	1.0	47
86	uPA/Plasmin System-Mediated MMP-9 Activation Is Implicated in Bronchial Epithelial Cell Migration. Experimental Cell Research, 2001, 264, 326-336.	1.2	101
87	Matriptase and HAI-1 Are Expressed by Normal and Malignant Epithelial Cells in Vitro and in Vivo. American Journal of Pathology, 2001, 158, 1301-1311.	1.9	172
88	Prognostic Significance of the Combined Expression of Matrix Metalloproteinase-9, Urokinase Type Plasminogen Activator and its Receptor in Breast Cancer as Measured by Northern Blot Analysis. International Journal of Biological Markers, 2001, 16, 62-68.	0.7	25
89	The Role of the Plasminogen Activation System in Angiogenesis and Metastasis. Surgical Oncology Clinics of North America, 2001, 10, 393-415.	0.6	126
90	Pulmonary interstitial pressure and tissue matrix structure in acute hypoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L881-L887.	1.3	70

#	ARTICLE	IF	CITATIONS
91	Functional Evaluation of Plasmin Formation in Primary Breast Cancer. Journal of Clinical Oncology, 2001, 19, 2731-2738.	0.8	33
92	Matrix Metalloproteinases: From Biology to Therapeutic Strategies in Cardiovascular Disease. Journal of Investigative Medicine, 2001, 49, 381-397.	0.7	43
93	Role of cadherins and matrixins in melanoma. Current Opinion in Oncology, 2001, 13, 117-123.	1.1	33
94	Plasma Levels of Metalloproteinases-3 and -9 as Markers of Successful Abdominal Aortic Aneurysm Exclusion After Endovascular Graft Treatment. Circulation, 2001, 104, I-288-I-295.	1.6	112
95	Rapid Differential Endogenous Plasminogen Activator Expression After Acute Middle Cerebral Artery Occlusion. Stroke, 2001, 32, 1341-1348.	1.0	105
96	Inhibitory Role of Eosinophils on Cell Surface Plasmin Generation by Bronchial Epithelial Cells: Inhibitory Effects of Transforming Growth Factor β. Lung, 2001, 179, 9-20.	1.4	13
97	The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathology and Oncology Research, 2001, 7, 14-23.	0.9	533
98	The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis. Journal of Cutaneous Pathology, 2001, 28, 291-297.	0.7	15
99	Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer, 2001, 91, 822-832.	2.0	291
100	Regulation of urokinase plasminogen activator/plasmin- mediated invasion of melanoma cells by the integrin vitronectin receptor $\hat{l}\pm V\hat{l}^2$ 3. International Journal of Cancer, 2001, 91, 300-308.	2.3	10
101	Overexpression of homeobox geneHOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. International Journal of Cancer, 2001, 93, 516-525.	2.3	67
102	Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: A role for inflammatory cells in tumor invasion and angiogenesis. Journal of Cellular Physiology, 2001, 189, 197-206.	2.0	322
103	Functional role of matrix metalloproteinases (MMPs) in mammary epithelial cell development. Journal of Cellular Physiology, 2001, 188, 75-88.	2.0	28
104	Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer. Gynecologic Oncology, 2001, 82, 291-298.	0.6	96
105	Plasmin-independent gelatinase B (matrix metalloproteinase-9) release by monocytes under the influence of urokinase. Biochemistry (Moscow), 2001, 66, 954-959.	0.7	12
106	Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Research and Treatment, 2001, 70, 197-204.	1.1	64
107	The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. British Journal of Cancer, 2001, 84, 1363-1371.	2.9	41
108	Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. British Journal of Cancer, 2001, 85, 772-779.	2.9	132

#	Article	IF	CITATIONS
109	Bacterial plasminogen activators and receptors. FEMS Microbiology Reviews, 2001, 25, 531-552.	3.9	262
110	In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Therapy, 2001, 8, 534-541.	2.3	30
111	Membrane-type 1 matrix metalloproteinase is induced in decidual stroma without direct invasion by trophoblasts. Molecular Human Reproduction, 2001, 7, 271-277.	1.3	9
112	Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1104-1117.	1.1	701
113	Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1. Journal of Biological Chemistry, 2001, 276, 8135-8141.	1.6	149
114	KiSS-1 Represses 92-kDa Type IV Collagenase Expression by Down-regulating NF-κB Binding to the Promoter as a Consequence of lκBα-induced Block of p65/p50 Nuclear Translocation. Journal of Biological Chemistry, 2001, 276, 1164-1172.	1.6	177
115	Activation of Matrix Metalloproteinase-2 by a Novel Oral Spirochetal Species Treponema lecithinolyticum. Journal of Periodontology, 2001, 72, 1594-1600.	1.7	28
116	Antiplasmin Activity of a Peptide That Binds to the Receptor-binding Site of Angiogenin. Journal of Biological Chemistry, 2002, 277, 9690-9694.	1.6	15
117	Collagen Dissolution by Keratinocytes Requires Cell Surface Plasminogen Activation and Matrix Metalloproteinase Activity. Journal of Biological Chemistry, 2002, 277, 45154-45161.	1.6	70
118	Gonadotropin Surge-Induced Up-Regulation of the Plasminogen Activators (Tissue Plasminogen) Tj ETQq1 1 0.78 Within Bovine Periovulatory Follicular and Luteal Tissue1. Biology of Reproduction, 2002, 66, 1413-1421.	4314 rgB1 1.2	Overlock 1 46
119	Factor Xa Releases Matrix Metalloproteinase-2 (MMP-2) From Human Vascular Smooth Muscle Cells and Stimulates the Conversion of Pro–MMP-2 to MMP-2. Circulation Research, 2002, 90, 1122-1127.	2.0	57
120	The Role of Proteases in Fibronectin Matrix Remodeling in Thyroid Epithelial Cell Monolayer Cultures. Biological Chemistry, 2002, 383, 167-76.	1.2	7
121	The Molecular Basis for Anti-Proteolytic and Non-Proteolytic Functions of Plasminogen Activator Inhibitor Type-1: Roles of the Reactive Centre Loop, the Shutter Region, the Flexible Joint Region and the Small Serpin Fragment. Biological Chemistry, 2002, 383, 21-36.	1.2	67
122	Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. Journal of Cell Science, 2002, 115, 3767-3777.	1.2	45
123	MT1-MMP-Dependent and -Independent Regulation of Gelatinase A Activation in Long-Term, Ascorbate-Treated Fibroblast Cultures: Regulation by Fibrillar Collagen. Experimental Cell Research, 2002, 272, 109-118.	1.2	25
124	Stimulation of Matrix Metalloproteinase-9 Expression in Human Fibrosarcoma Cells by Synthetic Matrix Metalloproteinase Inhibitors. Experimental Cell Research, 2002, 275, 110-121.	1.2	27
125	Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. Journal of the American College of Cardiology, 2002, 39, 1384-1391.	1.2	135
126	Inhibition of urokinase-type plasminogen activator delays expression of c-jun, activated transforming growth factor $\hat{l}^21$ , and matrix metalloproteinase 2 during post-hepatectomy liver regeneration in mice. Journal of Hepatology, 2002, 36, 637-644.	1.8	8

#	Article	IF	CITATIONS
127	Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis. Neuroscientist, 2002, 8, 586-595.	2.6	106
128	Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. BMC Cancer, 2002, 2, 17.	1.1	8
129	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. European Journal of Haematology, 2002, 69, 43-49.	1.1	11
130	Matrix metalloproteinases in neuroinflammation. Glia, 2002, 39, 279-291.	2.5	777
131	Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. International Journal of Cancer, 2002, 98, 23-28.	2.3	48
132	Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. Journal of Cellular Physiology, 2002, 192, 160-170.	2.0	140
133	Molecular mechanisms of renal allograft fibrosis. British Journal of Surgery, 2002, 88, 1429-1441.	0.1	54
134	Increased Migration of Murine Keratinocytes Under Hypoxia Is Mediated by Induction of Urokinase Plasminogen Activator. Journal of Investigative Dermatology, 2002, 119, 1304-1309.	0.3	31
135	Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 919-927.	0.4	36
136	Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene, 2002, 21, 5213-5223.	2.6	194
137	Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2. Oncogene, 2002, 21, 8128-8139.	2.6	35
138	(-)Epigallocatechin-3-Gallate Directly Inhibits MT1-MMP Activity, Leading to Accumulation of Nonactivated MMP-2 at the Cell Surface. Laboratory Investigation, 2002, 82, 1685-1693.	1.7	54
139	Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clinical and Experimental Metastasis, 2002, 19, 527-534.	1.7	50
140	Modulation of proteolytic potential and differentiation by CNTF and BDNF in two mouse neuroblastoma clones: relation to invasion. Clinical and Experimental Metastasis, 2002, 19, 709-716.	1.7	7
141	Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer and Metastasis Reviews, 2003, 22, 153-166.	2.7	141
142	Clinical implications of matrix metalloproteinases. Molecular and Cellular Biochemistry, 2003, 252, 305-329.	1.4	135
143	Angiogenin in sera as an independent prognostic factor in gastric cancer. Journal of Cancer Research and Clinical Oncology, 2003, 129, 239-244.	1.2	17
144	Functional significance of MMP-2 and MMP-9 expression by human malignant oral keratinocyte cell lines. Archives of Oral Biology, 2003, 48, 779-786.	0.8	19

#	ARTICLE	IF	CITATIONS
145	Urokinase Receptor is Up-regulated in Endothelial Cells and Macrophages Associated with Fibrinoid Deposits in the Human Placenta. Placenta, 2003, 24, 677-685.	0.7	17
146	Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. Journal of Cellular Biochemistry, 2003, 88, 1188-1201.	1.2	23
147	Cerebral Microvessel Responses to Focal Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 879-894.	2.4	576
148	Activation Systems for Latent Matrix Metalloproteinase-2 are Upregulated Immediately after Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1408-1419.	2.4	123
149	Overview of Novel Anticancer Drug Targets. , 2003, 85, 03-28.		1
150	Nonoxidative ethanol metabolites alter extracellular matrix protein content in rat pancreas. Gastroenterology, 2003, 125, 1845-1859.	0.6	45
151	Proteolysis in Carcinogenesis., 2003, , 137-149.		4
152	The effect of TGF- $\hat{l}^22$ on human trabecular meshwork extracellular proteolytic system. Experimental Eye Research, 2003, 77, 757-765.	1.2	118
153	p11 Regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB Journal, 2003, 17, 235-246.	0.2	68
154	The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by AÌŠ6 Suggests a New Therapeutic Target. , 2003, 44, 2736.		47
155	Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (â^*)epigallocatechin-3-gallate. Journal of Leukocyte Biology, 2003, 74, 88-94.	1.5	36
156	VEGFâ€induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB Journal, 2003, 17, 752-754.	0.2	111
157	Plasminogen activation at the cell surface. Current Topics in Developmental Biology, 2003, 54, 263-312.	1.0	36
158	Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells in Vitro and in Vivo. Recent Results in Cancer Research, 2003, 162, 43-63.	1.8	16
159	Plasminogen Activator Inhibitor-1 in Patients with Kawasaki Disease: Diagnostic Value for the Prediction of Coronary Artery Lesion and Implication for a New Mode of Therapy. Pediatric Research, 2003, 53, 983-988.	1.1	24
160	Surface association of secreted matrix metalloproteinases. Current Topics in Developmental Biology, 2003, 54, 75-100.	1.0	15
161	Myogenic and nonmyogenic cells differentially express proteinases, Hsc/Hsp70, and BAG-1 during skeletal muscle regeneration. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E206-E215.	1.8	58
162	Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood, 2003, 101, 1810-1817.	0.6	143

#	Article	IF	CITATIONS
163	Exploitation of Astrocytes by Glioma Cells to Facilitate Invasiveness: A Mechanism Involving Matrix Metalloproteinase-2 and the Urokinase-Type Plasminogen Activator–Plasmin Cascade. Journal of Neuroscience, 2003, 23, 4034-4043.	1.7	163
164	Fibrinolysis in LPS-induced chronic airway disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L940-L948.	1.3	39
165	Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. Journal of Cell Science, 2004, 117, 1847-1857.	1.2	136
166	Expression of Chicken Ovalbumin Upstream Promoter-Transcription Factor II Enhances Invasiveness of Human Lung Carcinoma Cells. Cancer Research, 2004, 64, 5097-5105.	0.4	38
167	Intracellular and Cell Surface Localization of a Complex between $\hat{l}\pm M\hat{l}^22$ Integrin and Promatrix Metalloproteinase-9 Progelatinase in Neutrophils. Journal of Immunology, 2004, 172, 7060-7068.	0.4	54
168	Regulation of Gelatinases Expression by Cytokines, Endotoxin, and Pharmacological Agents in the Human Osteoarthritic Knee. Connective Tissue Research, 2004, 45, 142-150.	1.1	23
169	The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO Journal, 2004, 23, 3758-3768.	3.5	95
170	Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene, 2004, 23, 5041-5048.	2.6	122
171	Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer and Prostatic Diseases, 2004, 7, 327-332.	2.0	96
172	The role of gelatinases in colorectal cancer progression and metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 69-89.	3.3	290
173	Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. Journal of NeuroVirology, 2004, 10, 21-28.	1.0	56
174	Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. International Journal of Cancer, 2004, 112, 329-334.	2.3	29
175	Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (?)epigallocatechin-3-gallate. International Journal of Cancer, 2004, 112, 787-792.	2.3	69
176	Prostate carcinoma and green tea: (â^')epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. International Journal of Cancer, 2004, 112, 823-829.	2.3	48
177	Zymogen activation and characterization of a major gelatin-cleavage activity localized to the sea urchin extraembryonic matrix. Journal of Cellular Biochemistry, 2004, 93, 1075-1083.	1.2	5
178	PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. Journal of Cellular Physiology, 2004, 200, 297-308.	2.0	<b>7</b> 5
179	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Critical Reviews in Oncology/Hematology, 2004, 50, 87-100.	2.0	308
180	Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Research, 2004, 6, R157-69.	2.2	48

#	Article	IF	CITATIONS
181	Homocysteine modulates the proteolytic potential of human vascular endothelial cells. Biochemical and Biophysical Research Communications, 2004, 316, 170-176.	1.0	23
182	An Engineered Biopolymer Prevents Mucositis Induced by 5-Fluorouracil in Hamsters. American Journal of Pathology, 2004, 164, 739-746.	1.9	42
183	Gelatinase-mediated migration and invasion of cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1755, 37-69.	3.3	373
184	Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes. Journal of Cellular Physiology, 2005, 203, 156-165.	2.0	38
185	Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF- $\hat{l}^2$ 1-stimulated smooth muscle cells is pp60c-src/MEK-dependent. Journal of Cellular Physiology, 2005, 204, 236-246.	2.0	57
186	Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology, 2005, 41, 857-867.	3.6	131
187	Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clinical and Experimental Metastasis, 2005, 22, 643-652.	1.7	54
188	Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell International, 2005, 5, 1.	1.8	69
189	S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Frontiers in Bioscience - Landmark, 2005, 10, 300.	3.0	153
190	Neutrophil P-selectin-glycoprotein-ligand-1 binding to platelet P-selectin enhances metalloproteinase 2 secretion and platelet-neutrophil aggregation. Thrombosis and Haemostasis, 2005, 94, 1230-1235.	1.8	32
191	The urokinase plasminogen activator and its receptor. Thrombosis and Haemostasis, 2005, 93, 205-211.	1.8	136
192	Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. European Respiratory Journal, 2005, 25, 104-109.	3.1	36
193	Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas. Journal of Biological Chemistry, 2005, 280, 21882-21892.	1.6	124
194	Matrix Metalloproteinase-9 in Macrophages Induces Thymic Neovascularization following Thymocyte Apoptosis. Journal of Immunology, 2005, 174, 846-853.	0.4	26
195	Mechanisms of the Inhibitory Effect of Epigallocatechin-3-Gallate on Cultured Human Vascular Smooth Muscle Cell Invasion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1864-1870.	1.1	44
196	Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Experimental Cell Research, 2005, 303, 22-31.	1.2	33
198	Dermal fibroblasts from pseudoxanthoma elasticum patients have raised MMP-2 degradative potential. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 42-47.	1.8	41
199	Basal membrane remodeling during follicle histogenesis in the rat ovary: contribution of proteinases of the MMP and PA families. Developmental Biology, 2005, 277, 403-416.	0.9	39

#	Article	IF	CITATIONS
200	Amino-Terminal Fragment of Urokinase Inhibits Tumor Cell InvasionIn VitroandIn Vivo: Respective Contribution of the Urokinase Plasminogen Activator Receptor-Dependent or -Independent Pathway. Human Gene Therapy, 2005, 16, 1157-1167.	1.4	25
201	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. , 2006, , 1-35.		0
202	Biomarqueurs tissulaires tumoraux. Cancer du sein. Facteurs pronostiques, facteurs prédictifs. Quels standards en 2005 ?. , 2006, , 83-130.		0
203	Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging. FASEB Journal, 2006, 20, 1118-1130.	0.2	50
204	Making the cut: Protease-mediated regulation of angiogenesis. Experimental Cell Research, 2006, 312, 608-622.	1.2	177
205	Trypsins and their role in carcinoma growth. Experimental Cell Research, 2006, 312, 1219-1228.	1.2	76
207	Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. Clinica Chimica Acta, 2006, 372, 167-172.	0.5	18
208	The effect of IL-1 $\hat{l}$ ± on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells. Life Sciences, 2006, 78, 1975-1982.	2.0	24
209	Effect of compressive force on the expression of MMPs, PAs, and their inhibitors in osteoblastic Saos-2 cells. Life Sciences, 2006, 79, 575-583.	2.0	21
210	Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-α (TNF-α)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. Journal of Molecular and Cellular Cardiology, 2006, 41, 138-148.	0.9	104
211	Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse. Neuroscience, 2006, 140, 835-848.	1.1	22
212	MMPs - Role in Cardiovascular Development and Disease. Frontiers in Bioscience - Landmark, 2006, 11, 447.	3.0	91
213	Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee. Clinical Orthopaedics and Related Research, 2006, 447, 172-178.	0.7	13
214	EFFECT OF A NOVEL OCTAPEPTIDE UROKINASE FRAGMENT, AËŠ6, ON EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION IN THE MONKEY. Retina, 2006, 26, 202-209.	1.0	13
215	The p75NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clinical and Experimental Metastasis, 2006, 23, 107-116.	1.7	16
216	Mechanisms of angiogenesis in gliomas. Journal of Neuro-Oncology, 2006, 78, 281-293.	1.4	143
217	Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 195-202.	1.1	44
218	Matriptase and its putative role in cancer. Cellular and Molecular Life Sciences, 2006, 63, 2968-2978.	2.4	158

#	Article	IF	CITATIONS
219	Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 393-401.	1.9	12
220	Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin $\hat{I}^3$ -2 chain is an early coordinated event in incipient oral squamous cell carcinoma. International Journal of Cancer, 2006, 118, 2948-2956.	2.3	68
221	Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation. Journal of Biological Chemistry, 2006, 281, 10337-10346.	1.6	108
222	The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Archives of Disease in Childhood, 2006, 91, 847-851.	1.0	66
223	Mast cell-dependent activation of pro matrix metalloprotease 2: a role for serglycin proteoglycan-dependent mast cell proteases. Biological Chemistry, 2006, 387, 1513-9.	1.2	17
224	Urokinase Receptors Are Required for $\hat{l}\pm5\hat{l}^21$ Integrin-mediated Signaling in Tumor Cells. Journal of Biological Chemistry, 2007, 282, 3929-3939.	1.6	93
225	Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1282-H1290.	1.5	69
226	p75 Neurotrophin Receptor Inhibits Invasion and Metastasis of Gastric Cancer. Molecular Cancer Research, 2007, 5, 423-433.	1.5	57
227	Interaction between Cancer Cells and Stromal Fibroblasts Is Required for Activation of the uPAR-uPA-MMP-2 Cascade in Pancreatic Cancer Metastasis. Clinical Cancer Research, 2007, 13, 3115-3124.	3.2	84
228	Proteoglycan fragmentation and respiratory mechanics in mechanically ventilated healthy rats. Journal of Applied Physiology, 2007, 103, 747-756.	1.2	64
229	Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochemical Journal, 2007, 405, 547-558.	1.7	35
230	A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis. Experimental Neurology, 2007, 207, 350-356.	2.0	23
231	PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. Neoplasia, 2007, 9, 927-937.	2.3	36
232	Immunohistochemical detection of uPA, uPAR, PAIâ€1, and maspin in ameloblastic tumors. Journal of Oral Pathology and Medicine, 2007, 36, 488-494.	1.4	16
233	Association of gene polymorphisms for plasminogen activators with alveolar bone loss. Journal of Periodontal Research, 2007, 42, 305-310.	1.4	9
234	Could the Defects in the Endometrial Extracellular Matrix During the Implantation Be a Cause for Impaired fertility?. American Journal of Reproductive Immunology, 2007, 57, 40-48.	1.2	28
235	Effect of Semecarpus anacardium nut extract on ECM and proteases in mammary carcinoma rats. Vascular Pharmacology, 2007, 46, 419-426.	1.0	9
236	Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP. Neurobiology of Disease, 2007, 28, 304-315.	2.1	51

#	Article	IF	CITATIONS
237	Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. Clinical Biochemistry, 2008, 41, 109-116.	0.8	23
238	Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. Journal of Orthopaedic Research, 2008, 26, 475-484.	1.2	29
239	The arthritis severity locus <i>Cia5d</i> is a novel genetic regulator of the invasive properties of synovial fibroblasts. Arthritis and Rheumatism, 2008, 58, 2296-2306.	6.7	41
240	Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Molecular and Cellular Neurosciences, 2008, 37, 135-142.	1.0	49
241	Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis. Clinica Chimica Acta, 2008, 387, 90-96.	0.5	22
242	Novel MMP-9 Substrates in Cancer Cells Revealed by a Label-free Quantitative Proteomics Approach. Molecular and Cellular Proteomics, 2008, 7, 2215-2228.	2.5	147
243	Chapter 15 Experimental models in intracerebral hemorrhage. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 92, 307-324.	1.0	3
244	Plasmin-Matrix Metalloproteinase Cascades in Spinal Response to an Experimental Disc Lesion in Pig. Spine, 2008, 33, 839-844.	1.0	27
245	Metaloproteinases 1 e 7 e câncer colorretal. Revista Brasileira De Coloproctologia, 2008, 28, 353-362.	0.2	7
246	Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180. Journal of Cell Science, 2009, 122, 4042-4048.	1.2	60
247	Regulatory Mechanism of Matrix Metalloprotease-2 Enzymatic Activity by Factor Xa and Thrombin. Journal of Biological Chemistry, 2009, 284, 23375-23385.	1.6	22
248	Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacologica Sinica, 2009, 30, 1537-1542.	2.8	60
249	Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sciences, 2009, 84, 194-204.	2.0	90
251	Potentiation of cell invasion and matrix metalloproteinase production by $\hat{l}\pm3\hat{l}^21$ integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clinical and Experimental Metastasis, 2010, 27, 197-205.	1.7	30
252	Urokinase-Type Plasminogen Activator Induces BV-2 Microglial Cell Migration Through Activation of Matrix Metalloproteinase-9. Neurochemical Research, 2010, 35, 976-985.	1.6	19
253	Induction of matrix metalloproteinases and a collagenâ€degrading phenotype in fibroblasts and epithelial cells by secreted Porphyromonas gingivalis proteinase. Journal of Periodontal Research, 1998, 33, 408-420.	1.4	33
254	Hypoxia promotes metastasis in human gastric cancer by upâ€regulating the 67â€kDa laminin receptor. Cancer Science, 2010, 101, 1653-1660.	1.7	43
255	Obstructive renal injury: from fluid mechanics to molecular cell biology. Research and Reports in Urology, 2010, Volume 2, 41-55.	0.6	22

#	Article	IF	CITATIONS
256	Inhibition of the Proprotein Convertases Represses the Invasiveness of Human Primary Melanoma Cells with Altered p53, CDKN2A and N-Ras Genes. PLoS ONE, 2010, 5, e9992.	1.1	16
257	Plasminogen Activator Inhibitor-1 Regulates Myoendothelial Junction Formation. Circulation Research, 2010, 106, 1092-1102.	2.0	45
258	Thrombin-dependent MMP-2 Activity Is Regulated by Heparan Sulfate. Journal of Biological Chemistry, 2010, 285, 41270-41279.	1.6	24
259	Inhibition of proteases involved in embryo implantation by cholesterol sulfate. Human Reproduction, 2010, 25, 192-197.	0.4	7
260	Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee. Clinica Chimica Acta, 2010, 411, 1788-1792.	0.5	17
261	A chimera of green fluorescent protein with gelatinase binding and tumor targeting peptide. Protein Expression and Purification, 2010, 72, 234-237.	0.6	3
262	Gene Expression Profiling of Preovulatory Follicle in the Buffalo Cow: Effects of Increased IGF-I Concentration on Periovulatory Events. PLoS ONE, 2011, 6, e20754.	1.1	27
263	Regulation of DNA Repair Mechanism in Human Glioma Xenograft Cells both In Vitro and In Vivo in Nude Mice. PLoS ONE, 2011, 6, e26191.	1.1	20
264	Activation of matrix metalloproteinases following anti-A $\hat{l}^2$ immunotherapy; implications for microhemorrhage occurrence. Journal of Neuroinflammation, 2011, 8, 115.	3.1	32
265	Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9. Reproduction, 2011, 141, 227-239.	1.1	30
266	Dual Targets for Mouse Mast Cell Protease-4 in Mediating Tissue Damage in Experimental Bullous Pemphigoid. Journal of Biological Chemistry, 2011, 286, 37358-37367.	1.6	55
267	Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1378-H1386.	1.5	26
268	uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. Thorax, 2012, 67, 477-487.	2.7	42
269	Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-21.	3.0	133
270	Dimerization of Matrix Metalloproteinase-2 (MMP-2). Journal of Biological Chemistry, 2012, 287, 22643-22653.	1.6	27
271	Recent Findings on the Role of Gelatinases (Matrix Metalloproteinase-2 and -9) in Osteoarthritis. Advances in Orthopedics, 2012, 2012, 1-7.	0.4	51
272	Renoprotective Action of a Matrix Metalloproteinase Inhibitor in Progressive Mesangioproliferative Nephritis. Nephron Extra, 2012, 2, 133-146.	1.1	1
273	Fibrin(ogen)-Independent Role of Plasminogen Activators in Acetaminophen-Induced Liver Injury. American Journal of Pathology, 2012, 180, 2321-2329.	1.9	35

#	ARTICLE	IF	CITATIONS
274	Staurosporine induces ganglion cell differentiation in part by stimulating urokinase-type plasminogen activator expression and activation in the developing chick retina. Biochemical and Biophysical Research Communications, 2012, 423, 67-72.	1.0	9
275	Soluble E-cadherin: more than a symptom of disease. Frontiers in Bioscience - Landmark, 2012, 17, 1948.	3.0	84
276	Activity-Dependent Local Translation of Matrix Metalloproteinase-9. Journal of Neuroscience, 2012, 32, 14538-14547.	1.7	110
277	Effects of Tepary Bean ( <i>Phaseolus acutifolius</i> ) Protease Inhibitor and Semipure Lectin Fractions on Cancer Cells. Nutrition and Cancer, 2012, 64, 1269-1278.	0.9	36
278	Pro-Inflammatory Cytokines and Gelatinases in Climatic Droplet Keratopathy., 2012, 53, 3527.		20
279	Impact of mechanical ventilation and fluid load on pulmonary glycosaminoglycans. Respiratory Physiology and Neurobiology, 2012, 181, 308-320.	0.7	16
280	TGF-Î <sup>2</sup> 2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression. Experimental Eye Research, 2013, 115, 13-21.	1.2	25
281	High MMPâ€9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics, Part A, 2013, 161, 1897-1903.	0.7	140
282	TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. Cellular Signalling, 2013, 25, 490-500.	1.7	24
283	Molecular cloning and tissue distribution of hyaluronan binding protein 2 (HABP2) in red sea bream Pagrus major. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2013, 165, 271-276.	0.7	4
284	Targeting TNF- $\hat{l}_{\pm}$ suppresses the production of MMP-9 in human salivary gland cells. Archives of Oral Biology, 2013, 58, 1761-1768.	0.8	3
285	Inhibitory Effects of Dried Longan (Euphoria longana Lam.) Seed Extract on Invasion and Matrix Metalloproteinases of Colon Cancer Cells. Journal of Agricultural and Food Chemistry, 2013, 61, 3631-3641.	2.4	17
286	Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway. BioMed Research International, 2013, 2013, 1-10.	0.9	13
287	Hemostasis and Alterations of the Central Nervous System. Seminars in Thrombosis and Hemostasis, 2013, 39, 856-875.	1.5	25
288	Signaling Determinants of Glioma Cell Invasion. Advances in Experimental Medicine and Biology, 2013, 986, 121-141.	0.8	67
289	Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma. Molecular Cancer Research, 2013, 11, 1611-1623.	1.5	66
290	Ceramide 1-Phosphate Mediates Endothelial Cell Invasion via the Annexin a2-p11 Heterotetrameric Protein Complex. Journal of Biological Chemistry, 2013, 288, 19726-19738.	1.6	40
291	Surface $\hat{l}_{\pm}$ -Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target. PLoS ONE, 2013, 8, e69354.	1.1	98

#	Article	IF	CITATIONS
292	Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma. Scientific World Journal, The, 2013, 2013, 1-11.	0.8	74
293	S100A10: A Key Regulator of Fibrinolysis. , 0, , .		1
294	Invasive Potential of Melanoma Cells Correlates with the Expression of MT1-MMP and Regulated by Modulating Its Association with Motility Receptors via N-Glycosylation on the Receptors. BioMed Research International, 2014, 2014, 1-10.	0.9	10
295	Comprehensive proteomic analysis of a Chinese 2â€herb formula (Astragali Radix and Rehmanniae Radix) on mature endothelial cells. Proteomics, 2014, 14, 2089-2103.	1.3	7
296	Nitric oxide-matrix metaloproteinase-9 interactions: Biological and pharmacological significance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 603-617.	1.9	79
297	Plasmin-Dependent Modulation of the Blood–Brain Barrier: A Major Consideration during tPA-Induced Thrombolysis?. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1283-1296.	2.4	89
298	Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K–AKT and RhoA pathways after carbon ion irradiation. FEBS Letters, 2014, 588, 3240-3250.	1.3	39
299	Unilateral ureteral obstruction: beyond obstruction. International Urology and Nephrology, 2014, 46, 765-776.	0.6	157
300	Hyperglycemia-Suppressed Expression of Serpine1 Contributes to Delayed Epithelial Wound Healing in Diabetic Mouse Corneas., 2015, 56, 3383.		25
301	The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis. SpringerPlus, 2015, 4, 179.	1.2	9
302	Membraneâ€Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factorâ€2 Binding to the Cell Surface and Intracellular Signaling. Journal of Cellular Physiology, 2015, 230, 366-377.	2.0	13
303	Increased Urokinase-Type Plasminogen Activator Receptor Expression on Circulating Monocytes Is Correlated with Clinical Instability and Long-Term Adverse Cardiac Events in Patients with Coronary Artery Disease. Cardiology, 2016, 135, 98-107.	0.6	2
304	Proteases and Protease Inhibitors in Male Reproduction. , 2017, , 195-216.		3
305	JMJD3 and NF-ΰB-dependent activation of Notch1 gene is required for keratinocyte migration during skin wound healing. Scientific Reports, 2017, 7, 6494.	1.6	47
306	Proteases as prognostic markers in human and canine cancers. Veterinary and Comparative Oncology, 2017, 15, 669-683.	0.8	16
307	Extracellular Collagen Promotes Interleukin-1β–Induced Urokinase-Type Plasminogen Activator Production by Human Corneal Fibroblasts. , 2017, 58, 1487.		12
308	Transcriptional profiling validates involvement of extracellular matrix and proteinases genes in mouse gonad development. Mechanisms of Development, 2018, 149, 9-19.	1.7	31
309	Increased TIMP-3 expression alters the cellular secretome through dual inhibition of the metalloprotease ADAM10 and ligand-binding of the LRP-1 receptor. Scientific Reports, 2018, 8, 14697.	1.6	23

#	Article	IF	Citations
310	Methanol fixed fibroblasts serve as feeder cells to maintain stem cells in the pluripotent state in vitro. Scientific Reports, 2018, 8, 7780.	1.6	9
311	The inner ear proteome of fish. FEBS Journal, 2019, 286, 66-81.	2.2	48
312	Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population. Journal of Oral Biology and Craniofacial Research, 2019, 9, 226-229.	0.8	4
313	In situ 3D visualization of biomineralization matrix proteins. Journal of Structural Biology, 2020, 209, 107448.	1.3	10
314	Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. Frontiers in Neuroscience, 2021, 15, 688090.	1.4	108
315	Correlation of Serum Cystatin C with Renal Function in Gout Patients with Renal Injury. Journal of Interferon and Cytokine Research, 2021, 41, 329-335.	0.5	2
316	Regulation of urokinase plasminogen activator/plasmin―mediated invasion of melanoma cells by the integrin vitronectin receptor αVβ3. International Journal of Cancer, 2001, 91, 300-308.	2.3	47
317	Role of Annexin II Tetramer in the Regulation of Plasmin Activity. Molecular Biology Intelligence Unit, 2003, , 218-233.	0.2	5
318	Novel Molecular Targets for Cancer Drug Discovery. , 2002, , 521-540.		4
319	Therapeutic Potential of siRNA-mediated Targeting of Urokinase Plasminogen Activator, Its Receptor, and Matrix Metalloproteinases. Methods in Molecular Biology, 2009, 487, 1-15.	0.4	24
320	Signaling Determinants of Glioma Cell Invasion. Advances in Experimental Medicine and Biology, 2020, 1202, 129-149.	0.8	73
321	Matrix Metalloproteinases in Neuroinflammation and Cerebral Ischemia. , 2004, , 1-16.		17
322	Pathophysiology, Epidemiology, and Prognosis. , 2006, , 543-559.		7
323	72-kDa Gelatinase (Gelatinase A): Structure, Activation, Regulation, and Substrate Specificity. , 1998, , 85-113.		50
324	Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochemical Journal, 2001, 355, 397.	1.7	38
325	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640.	0.2	90
326	Plasma Levels of Metalloproteinases-3 and -9 as Markers of Successful Abdominal Aortic Aneurysm Exclusion After Endovascular Graft Treatment. Circulation, 2001, 104, .	1.6	3
327	Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. Journal of Clinical Investigation, 2005, 115, 879-887.	3.9	91

#	Article	IF	CITATIONS
328	Resistance of young gelatinase B–deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. Journal of Clinical Investigation, 1999, 104, 1507-1515.	3.9	265
329	Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. Journal of Clinical Investigation, 2000, 105, 1641-1649.	3.9	739
330	The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development (Cambridge), 2001, 128, 3117-3131.	1.2	317
331	TGF- $\hat{l}^21$ -induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. Journal of Cell Science, 2001, 114, 3905-3914.	1.2	113
332	Proteolysis during Tumor Cell Extravasation In Vitro: Metalloproteinase Involvement across Tumor Cell Types. PLoS ONE, 2013, 8, e78413.	1.1	35
333	Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b ( $\hat{l}\pm M$ ). PLoS ONE, 2014, 9, e85349.	1.1	34
334	Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histology and Histopathology, 2006, 21, 519-31.	0.5	42
335	Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. Oncotarget, 2016, 7, 47720-47737.	0.8	17
336	Matrix metalloproteinases in the process of invasion and metastasis of breast cancer. Archive of Oncology, 2006, 14, 136-140.	0.2	12
337	Protease activity of 80 kDa protein secreted from the apicomplexan parasite Toxoplasma gondii. Korean Journal of Parasitology, 2003, 41, 165.	0.5	6
338	Activation of Cancer Cell-Derived MMP-9 Correlates with Cancer Invasion-an in vitro study with 3-dimensional co-culture system Oral Medicine & Pathology, 2005, 10, 63-72.	0.3	1
339	Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 5931.	1.4	59
340	SEARCH FOR MOLECULAR TARGETS INVOLVED IN ORAL TUMOR INVASION. Japanese Jornal of Head and Neck Cancer, 2003, 29, 487-492.	0.1	1
343	Microvessel integrin expression during focal cerebral ischemia. , 2001, , 195-215.		0
344	Immunohistochemical Analysis of Urokinase-type Plasminogen Activator in pT3 or pT4 Colorectal Cancer Nihon Daicho Komonbyo Gakkai Zasshi, 2002, 55, 67-75.	0.1	0
345	Matrix Metalloproteinases and the Plasminogen System in Tumor Progression. , 2003, , 201-216.		0
346	Role of the Plasminogen Activator-Plasmin System in Angiogenesis. , 2003, , 269-290.		0
348	Role of Matrix Metalloproteinases in Bone Metastasis from Human Breast and Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2004, , 241-276.	0.1	0

#	Article	IF	CITATIONS
349	Amino-Terminal Fragment of Urokinase Inhibits Tumor Cell Invasion In Vitro and In Vivo: Respective Contribution of the Urokinase Plasminogen Activator Receptor-Dependent or -Independent Pathway. Human Gene Therapy, 2005, .	1.4	0
350	Dehydroepiandrosterone (DHEA). , 2011, , 432-444.		0
351	NSAID Induction of p75NTR in the Prostate: A Suppressor of Growth and Cell Migration Via the p38 MAPK Pathway. , 0, , .		1
352	Regulation of Proteolysis in Vascular Remodeling. , 2014, , 295-319.		0
353	Role of Proteases in Breast Cancer., 2017,, 3-22.		0
354	Biomarqueurs pronostiques LOE I/UC+++., 2007, , 185-195.		0
355	Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochemical Journal, 2000, 345 Pt 3, 511-9.	1.7	17
356	The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development (Cambridge), 2001, 128, 3117-31.	1.2	161
358	The ANXA2/S100A10 Complexâ€"Regulation of the Oncogenic Plasminogen Receptor. Biomolecules, 2021, 11, 1772.	1.8	8
359	Matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Journal of Chemical Sciences, 1999, 111, 239-254.	0.7	2
360	Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering. Postepy Dermatologii I Alergologii, 0, , .	0.4	0
361	Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2022, 48, e12804.	1.8	0
362	Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes. Histology and Histopathology, 2004, 19, 105-12.	0.5	27
363	Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. Histology and Histopathology, 2002, 17, 339-45.	0.5	53